



## Emerging Biotechnologies and Ethical Reflections in Clinical Practice

Melody Zozus\*

Department of Health and Human Services, University of Arkansas for Medical Sciences, AR, USA

### DESCRIPTION

In the ever-evolving landscape of healthcare, emerging biotechnologies have brought forth groundbreaking innovations that hold immense potential to transform clinical practice. These technologies encompass a range of scientific advancements, from gene editing and personalized medicine to regenerative therapies and artificial intelligence [1]. While these biotechnologies assure revolutionary benefits, they also raise complex ethical considerations that demand thoughtful reflection and careful integration into clinical practice. This article discusses the ethical dimensions surrounding emerging biotechnologies and their implications for ethical decision-making in the realm of healthcare [2].

The ethical framework of biotechnologies represents the convergence of scientific discoveries, technological prowess, and healthcare aspirations [3]. The profound impact of these innovations on human health necessitates a robust ethical framework that guides their development, deployment, and implementation. Several ethical principles serve as foundational pillars when navigating the uncharted territories of emerging biotechnologies. Biotechnologies should aim to maximize benefits while minimizing harm [4]. The potential benefits of these technologies, such as targeted therapies and enhanced diagnostics, can significantly improve patient outcomes. However, the risk of unintended consequences, including unforeseen health impacts and social inequalities, must be addressed to uphold non-maleficence. Respect for patients' autonomy requires that individuals have the right to make informed decisions about their medical care. In the context of emerging biotechnologies, this translates to the importance of obtaining informed consent. Patients should be adequately informed about the nature of the technology, potential risks, benefits, and alternatives before participating in these interventions [5].

Biotechnologies must be distributed equitably, ensuring that the benefits are accessible to all segments of society. Avoiding disparities in access and ensuring that vulnerable populations

are not disproportionately affected is essential for upholding principles of justice [6]. Many biotechnologies involve the collection and analysis of sensitive genetic and health data. Maintaining patient privacy and confidentiality becomes paramount, particularly as genomic data can reveal not only health risks but also information about family members [7]. Transparency in the development, testing, and implementation of biotechnologies fosters public trust. Accountability ensures that ethical considerations are consistently addressed and that potential adverse events are appropriately managed [8].

Ethical integrating emerging biotechnologies into clinical practice requires a balanced approach that prioritizes both innovation and ethical considerations [9]. Physicians must ensure that patients fully understand the nature of the biotechnology-based interventions, their potential risks, and benefits. Informed consent becomes even graver as the complexity of the technology increases. Collaboration between healthcare providers and patients is essential when considering biotechnological interventions. Patients' values, preferences, and understanding of the technology should guide decision-making [10].

### CONCLUSION

The integration of emerging biotechnologies into clinical practice represents an exciting frontier in healthcare. However, these innovations bring with them a range of ethical dilemmas that must be carefully addressed to ensure that their benefits are realized while minimizing potential harms. A comprehensive ethical framework that embraces principles such as beneficence, autonomy, justice, and accountability is essential for navigating the ethical terrain of biotechnologies. As healthcare professionals, researchers, policymakers, and society at large engage in thoughtful ethical reflections, they pave the way for responsible innovation that aligns with the core values of patient-centered care and human dignity. By fostering a harmonious relationship between technological advancement and ethical deliberation that can usher in a future where emerging biotechnologies amplify human well-being while upholding the principles that define the essence of healthcare.

**Correspondence to:** Melody Zozus, Department of Health and Human Services, University of Arkansas for Medical Sciences, AR, USA, E-mail: zozus.mel@uams.edu

**Received:** 28-May-2023, Manuscript No. JCRB-23-22682; **Editor assigned:** 31-May-2023, Pre QC No. JCRB-23-22682 (PQ); **Reviewed:** 14-Jun-2023, QC No JCRB-23-22682; **Revised:** 22-Jun-2023, Manuscript No. JCRB-23-22682 (R); **Published:** 30-Jun-2023, DOI: 10.35248/2155-9627.23.S14.010.

**Citation:** Zozus M (2023) Emerging Biotechnologies and Ethical Reflections in Clinical Practice. J Clin Res Bioeth. S14:010.

**Copyright:** © 2023 Zozus M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## REFERENCES

1. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med.*2018; 378(24):2288-2301.
2. Sakin A, Sahin S, Yasar N, Geredeli C, Aksaray F, et al. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. *Pulmonol.*2021; 27(1): 26-34.
3. Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, et al. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. *Lung Cancer.* 2021;161:26-33.
4. Santos FN, Cruz MR, Riera R. Chemotherapy for advanced non-small-cell lung cancer in elderly patients. *JAMA Oncol.*2016; 2(12): 1645-1646.
5. Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, et al. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. *Ann Oncol.*2014; 25(7):1270-1283.
6. Laviana AA, Luckenbaugh AN, Wallis CJ. Seeking the truth: Understanding the impact of missing data on the validity of the new surveillance, epidemiology and end results prostate with watchful waiting database. *Eur Urol.*2020; 78(3):345-346.
7. Tolwin Y, Gillis R, Peled N. Gender and lung cancer-EER-based analysis. *Ann Epidemiol.*2020; 46:14-9.
8. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group.2018
9. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): An open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol.*2017; 18(12): 1610-1623.
10. Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: Final results of an international phase II trial. *J Thorac Oncol.*2008; 3(9):994-1002.